Antibiotic Selection for Pneumonia in Patients with History of Lymphoma

Initial Assessment and Risk Stratification

The Infectious Diseases Society of America recommends assessing severity using clinical parameters to determine appropriate treatment setting (outpatient vs. inpatient vs. ICU) 1
Consider recent chemotherapy, neutropenia status, and previous antibiotic exposure as key factors in antibiotic selection, as suggested by the Infectious Diseases Society of America 3

For non-severe community-acquired pneumonia, the Infectious Diseases Society of America recommends a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) as first choice 1
For non-severe community-acquired pneumonia, an alternative is a β-lactam (high-dose amoxicillin or amoxicillin-clavulanate) plus a macrolide (azithromycin or clarithromycin), as recommended by the Infectious Diseases Society of America 1
For non-severe pneumonia requiring hospitalization, combined therapy with a β-lactam (cefotaxime, ceftriaxone, or ampicillin) plus a macrolide (clarithromycin or azithromycin) is recommended by the Infectious Diseases Society of America 1
For severe pneumonia requiring ICU admission, a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin or a respiratory fluoroquinolone is recommended by the Infectious Diseases Society of America 1

Consider empiric coverage for MRSA if patient has risk factors (prior IV antibiotics within 90 days), as suggested by the Infectious Diseases Society of America 3

For non-severe pneumonia, 7-10 days of treatment is typically sufficient, according to the Infectious Diseases Society of America 2
For severe pneumonia, 10-14 days of treatment is recommended by the British Thoracic Society 4
Extended treatment (14-21 days) may be necessary for certain pathogens like Legionella or when dealing with complications, as recommended by the British Thoracic Society 4

Arrange follow-up chest radiograph at around 6 weeks, especially for patients over 50 years, to rule out underlying malignancy or recurrence, as suggested by the Infectious Diseases Society of America 2
Monitor for clinical response within 48-72 hours; consider changing antibiotics if no improvement, as recommended by the British Thoracic Society 4

Delayed recognition of treatment failure is associated with increased mortality, according to the American Thoracic Society 5